Adaptive Biotechnologies

Adaptive Biotechnologies is a commercial-stage biotechnology company that leverages the natural biology of the adaptive immune system to transform the diagnosis and treatment of disease. Founded in 2009, the company is headquartered in Seattle, Washington, and is a leader in immune-driven medicine. Its core technology platform is designed to read and translate the genetic code of the immune system to develop clinical products across a range of conditions, including oncology, autoimmune disease, and infectious disease.

Company overview

Adaptive Biotechnologies was co-founded in 2009 by brothers Chad Robins and Harlan Robins, with Harlan's research from the Fred Hutchinson Cancer Research Center forming the scientific foundation. The company established its headquarters in the South Lake Union neighborhood of Seattle, a major hub for life sciences. Key leadership has included Chad Robins as CEO and Julie Rubinstein on its board of directors. The company completed its initial public offering on the NASDAQ under the ticker symbol ADPT in June 2019, raising significant capital to fund its research and commercial expansion. Its corporate mission centers on decoding the immune system to improve patient outcomes across a spectrum of diseases.

Technology and platform

The company's foundational technology is its proprietary immune medicine platform, which combines next-generation DNA sequencing (NGS) with advanced bioinformatics to at-scale profile the body's T-cell and B-cell receptors. This platform is built upon a massive database of immune receptor sequences, largely derived from collaborations with institutions like the Fred Hutchinson Cancer Research Center and Microsoft. The partnership with Microsoft specifically applies artificial intelligence and machine learning to map the relationships between immune receptors and their targets, known as antigens, for diseases like COVID-19 and Type 1 diabetes. This mapping initiative, known as the ImmuneCODE database, aims to create a universal diagnostic and therapeutic map of the immune system.

Clinical applications and products

Adaptive Biotechnologies has commercialized several products derived from its platform. Its first and most significant product is ClonoSEQ, a next-generation sequencing-based test used for the detection and monitoring of minimal residual disease (MRD) in patients with certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL). ClonoSEQ received FDA de novo clearance and is a recognized standard in clinical guidelines from organizations like the National Comprehensive Cancer Network (NCCN). For infectious disease, the company launched T-Detect, an FDA-authorized test that uses T-cell response to aid in the diagnosis of past COVID-19 infection. The company is also actively developing research applications in autoimmune disease and for monitoring immune response to therapies like CAR-T.

Collaborations and partnerships

The company has established numerous high-profile strategic collaborations to advance and commercialize its technology. Its landmark partnership with Microsoft, initiated in 2018, focuses on combining Adaptive's immunosequencing data with Microsoft's computational capabilities to model the immune system. In oncology, Adaptive has a major collaboration with Genentech, a member of the Roche Group, to develop and commercialize personalized neoantigen-targeted therapies. It also has a partnership with Amgen for target discovery in oncology. Additional significant agreements include those with the National Institutes of Health (NIH) for COVID-19 research and with Pacific Biosciences to develop high-resolution sequencing methods for immune receptors.

Financial performance and market

As a publicly traded company on the NASDAQ, Adaptive Biotechnologies' financial performance is driven by revenue from its ClonoSEQ test, its research services, and payments from collaborators like Genentech. The company's market valuation and growth are tied to the adoption of MRD testing in hematologic malignancies and the potential expansion into new disease areas. It operates in competitive markets alongside other diagnostic and life science companies such as Guardant Health, Foundation Medicine, and Quest Diagnostics. The company's financial results and strategic direction are regularly reviewed by analysts from firms like J.P. Morgan and Goldman Sachs, with its performance influenced by clinical data, regulatory milestones, and execution of its partnership agreements.

Category:Biotechnology companies of the United States Category:Companies based in Seattle Category:Companies listed on NASDAQ